AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics'…